Suppr超能文献

Corrigendum to "Low cytoplasmic NUB1 protein exerts hypoxic cell death with poorer prognosis in oestrogen receptor negative breast cancer patients" [Translational Oncology, volume 49 (2024), 102106].

作者信息

Tan Ka-Liong, Haider Syed, Zois Christos E, Hu Jianting, Turley Helen, Leek Russell, Buffa Francesca, Acuto Oreste, Harris Adrian L, Pezzella Francesco

机构信息

Tumour Pathology Laboratory, Nuffield Division of Clinical Laboratory Sciences, Radcliffe Department of Medicine, John Radcliffe Hospital, Headington, Oxford OX3 9DU, UK; Faculty of Medicine and Health Sciences, Universiti Sains Islam Malaysia (USIM), Persiaran Ilmu, Putra Nilai, 71800 Nilai, Negeri Sembilan, Malaysia.

Department of Oncology, University of Oxford, Old Road Campus Research Building, Roosevelt Drive, Oxford, OX3 7DQ, UK; Computational Biology and Integrative Genomics, Department of Oncology, Old Road Campus Research Building, Roosevelt Drive Oxford, University of Oxford, UK; The Breast Cancer Now Toby Robins Breast Cancer Research Centre, The Institute of Cancer Research, London, SW3 6JB, UK.

出版信息

Transl Oncol. 2025 May;55:102354. doi: 10.1016/j.tranon.2025.102354. Epub 2025 Mar 16.

DOI:10.1016/j.tranon.2025.102354
PMID:40221214
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12242585/
Abstract
摘要

相似文献

1
Corrigendum to "Low cytoplasmic NUB1 protein exerts hypoxic cell death with poorer prognosis in oestrogen receptor negative breast cancer patients" [Translational Oncology, volume 49 (2024), 102106].
Transl Oncol. 2025 May;55:102354. doi: 10.1016/j.tranon.2025.102354. Epub 2025 Mar 16.
2
Low cytoplasmic NUB1 protein exerts hypoxic cell death with poorer prognosis in oestrogen receptor negative breast cancer patients.
Transl Oncol. 2024 Nov;49:102106. doi: 10.1016/j.tranon.2024.102106. Epub 2024 Aug 24.
3
Mechanism and Predictive Role of NUB1 Protein in Oestrogen Receptor Pathway of FEC-Treated Breast Cancer Patients.
Biomedicines. 2025 May 27;13(6):1307. doi: 10.3390/biomedicines13061307.
4
LHRH agonists for adjuvant therapy of early breast cancer in premenopausal women.
Cochrane Database Syst Rev. 2009 Oct 7;2009(4):CD004562. doi: 10.1002/14651858.CD004562.pub4.
5
Hormone therapy use and young-onset breast cancer: a pooled analysis of prospective cohorts included in the Premenopausal Breast Cancer Collaborative Group.
Lancet Oncol. 2025 Jul;26(7):911-923. doi: 10.1016/S1470-2045(25)00211-6.
6
Targeting tumour re-wiring by triple blockade of mTORC1, epidermal growth factor, and oestrogen receptor signalling pathways in endocrine-resistant breast cancer.
Breast Cancer Res. 2018 Jun 8;20(1):44. doi: 10.1186/s13058-018-0983-1.
7
The safety and efficacy of controlled ovarian hyperstimulation for fertility preservation in women with early breast cancer: a systematic review.
Hum Reprod. 2017 May 1;32(5):1033-1045. doi: 10.1093/humrep/dex027.
8
Integrated proteomics and transcriptomics analysis reveals key regulatory genes between ER-positive/PR-positive and ER-positive/PR-negative breast cancer.
BMC Cancer. 2025 Jul 1;25(1):1048. doi: 10.1186/s12885-025-14451-y.
9
The clinical effectiveness and cost-effectiveness of genotyping for CYP2D6 for the management of women with breast cancer treated with tamoxifen: a systematic review.
Health Technol Assess. 2011 Sep;15(33):1-102. doi: 10.3310/hta15330.
10
Non-contraceptive oestrogen-containing preparations for controlling symptoms of premenstrual syndrome.
Cochrane Database Syst Rev. 2017 Mar 3;3(3):CD010503. doi: 10.1002/14651858.CD010503.pub2.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验